Comparative Pharmacology
Head-to-head clinical analysis: DEMECLOCYCLINE HYDROCHLORIDE versus DOXYCHEL HYCLATE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: DEMECLOCYCLINE HYDROCHLORIDE versus DOXYCHEL HYCLATE.
DEMECLOCYCLINE HYDROCHLORIDE vs DOXYCHEL HYCLATE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Binds to the 30S ribosomal subunit, inhibiting protein synthesis by preventing aminoacyl-tRNA from attaching to the mRNA-ribosome complex.
Tetracycline antibiotic; inhibits bacterial protein synthesis by binding to the 30S ribosomal subunit, preventing aminoacyl-tRNA binding to the mRNA-ribosome complex.
150 mg orally every 6 hours or 300 mg orally every 12 hours. Maximum daily dose: 1200 mg.
100 mg orally or IV every 12 hours on day 1, then 100 mg daily.
None Documented
None Documented
10-17 hours; prolonged in renal impairment (up to 40–50 hours)
Terminal elimination half-life is 18–22 hours in patients with normal renal function; prolonged to 20–30 hours in severe renal impairment. Clinical context: Allows once- or twice-daily dosing.
Renal: 40-50% unchanged; fecal/biliary: 10-15%
Doxycycline hyclate is primarily excreted via the feces (approximately 90%) as an inactive chelated complex, with renal excretion accounting for about 10% of the dose. Biliary excretion is minimal.
Category C
Category C
Tetracycline Antibiotic
Tetracycline Antibiotic